Manning F C
University of New Mexico School of Medicine, Albuquerque.
Am Fam Physician. 1994 Sep 15;50(4):819-26.
Tacrine, a centrally acting cholinesterase inhibitor, may improve cognitive and functional status in patients with mild to moderate Alzheimer's disease. In recent controlled trials, patients have shown improvement in cognitive assessment scores, but the clinical significance of such benefits remains unclear. Appropriate diagnostic evaluation is necessary to prevent inappropriate treatment in patients with non-Alzheimer's dementia. Hepatotoxicity and gastrointestinal symptoms are common adverse effects of tacrine, and frequent monitoring of liver function is required.
他克林，一种中枢性胆碱酯酶抑制剂，可能改善轻至中度阿尔茨海默病患者的认知和功能状态。在最近的对照试验中，患者的认知评估分数有所改善，但这种益处的临床意义仍不明确。进行适当的诊断评估对于防止非阿尔茨海默病性痴呆患者接受不恰当治疗很有必要。肝毒性和胃肠道症状是他克林常见的不良反应，需要频繁监测肝功能。
